Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Research Letters

A Third Dose of mRNA COVID-19 Vaccine Significantly Enhances Anti–SARS-CoV-2 Spike IgG Response in Nursing Home Residents in Italy

On behalf of the GeroCovid Vax Study Group*

To the Editor:

A rapid development of effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and their deployment has proved to be a highly successful strategy to reduce the impact of the COVID-19 pandemic. Several studies have suggested a waning of humoral responses after primary vaccination. A third dose of the mRNA vaccine was shown to increase neutralizing antibody levels and prevent severe outcomes. However, data on the response to third dose of SARS-CoV-2 vaccine in the frail and complex population in Nursing Homes (NHs) are still limited. In this context, we have assessed the trajectories of humoral immunity in a sample NH resident receiving a 3-dose SARS-CoV-2 vaccine schedule.

Data are from the GeroCOVID VAX project, a study promoted by the Italian Society of Gerontology and Geriatrics (SIGG) and the Italian National Institute of Health (Istituto Superiore di Sanità) and sponsored by the Italian Medicines Agency (AIFA). We present data based on a subsample of 144 residents with no clinical history of SARS-CoV-2 infection from 14 NHs in the Calabria Region of Italy. All participants received 2 doses of BNT162b2 vaccine 3 weeks apart and a third dose of an mRNA vaccine (either mRNA-1273 or BNT162b2) between 6 and 9 months from the first vaccine dose.

Humoral immunity was assessed by the Liaison SARS-CoV-2 TrimericS IgG assay (DiaSorin, Italy) on serum samples collected at 4 time points: prior to the first dose of vaccine (T0); 2 months after first vaccine dose (T1); 6 months after first vaccine dose (T2); and 2 months after third dose (T3). T2 assessment was always performed before the third dose. IgG antibody concentrations were expressed as binding antibody units (BAU/mL). According to manufacturer’s instructions, values ≥33.8 BAU/mL were interpreted as positive. Given the nonnormal distribution of SARS-CoV-2 TrimericS IgG antibody concentrations, statistical analyses were performed using log-transformed values and geometric means (GMs) were calculated. Analysis of variance was used to compare the GM across the 4 time points. T1 was used as the reference group. Differences in GM at T3 were tested across sex, age groups, and time from first vaccination.

The study was approved by the Italian National Ethical Committee with the permission number 264/2021 (January 26, 2021). Median age of 144 study participants was 85.2 years and 104 (72.2%) were female. Participants were vaccinated with 2 doses of BNT162b2. A third vaccination was administered with BNT162b2 (n=130) or mRNA-1273 (n=14) between 6 and 9 months after the first dose. The rate of participants with anti–TrimericS IgG levels above the positivity cutoff of the serologic test raised from 0% at T0 (prior to first dose) to 99% at T1 (1 month after second dose) and then declined to 81% at T2 (5 months after the second dose). At T3, 2 months after the third dose all participants (100%) exceeded the positivity threshold. As shown in Table 1, SARS-CoV-2 TrimericS IgG concentration at T1 was significantly higher than those observed at T0 and T2, but significantly lower than that measured at T3. A similar trend was observed in men and women and in both age groups considered. When GM differences were tested across sex and age groups for T3, we observed that participants aged <80 years had higher antibody levels as compared with those aged ≥80 years (GM = 4832.0 vs 3272.8 BAU/mL), but this association did not reach statistical significance (P = .08). No substantial difference was observed according to sex. Among participants receiving the third dose 8–9 months after first dose (n=114), GM at T3 was higher (3775.2 BAU/mL; SE = 400.9) as compared with those receiving third dose 6–7 months after first dose (n=30) (2996.7 BAU/mL; SE = 620.4), although not significant (P = .32).

The present study shows that among NH residents in Italy without prior SARS-CoV-2 infection, a third dose of mRNA SARS-CoV-2 vaccines significantly enhances the antibody response to the Spike protein, even in those residents ≥80 years of age. Therefore, we confirm and reinforce findings of a previous study suggesting a strong and rapid decay of humoral immunity after the second BNT162b2 dose and a high antibody response after the third dose. Moreover, our data show that an extended interval between the first and the third dose did not result in impaired immunogenicity, thus adding relevant information for the implementation of timely administered booster vaccinations among frail, older people who often present with an inadequate immune response. These real-world data are valuable for shaping ongoing and future vaccination campaigns.

References

1. Livingston EH. Necessity of 2 doses of the Pfizer and Moderna COVID-19 vaccines. JAMA. 2021;325:898.
2. McDade TW, Demombrenu AR, Sancilio A, et al. Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history. Sci Rep. 2021;11:17325.
3. Milne G, Hames T, Scotton C, et al. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? Lancet Respir Med. 2021;9:1450–1466.

* List of GeroCovid Vax Study Group members is available in reference 7.
Table 1

Geometric Means (GMs) and SEs of SARS-CoV-2 TrimericS IgG Serum Concentration at Baseline Assessment (Prior to Vaccination, T0), 2 and 6 Months After First Dose (T1 and T2), and 2 Months After Third Dose (T3) in Nursing Home Residents

| SARS-CoV-2 TrimericS IgG Serum Concentration, BAU/mL | T0: Prior to Vaccination |   |   |   | T1: 2 mo After First Dose |   |   |   | T2: 6 mo After First Dose |   |   |   | T3: 2 mo After Third Dose |
|-----------------------------------------------------|--------------------------|---|---|---|--------------------------|---|---|---|--------------------------|---|---|---|--------------------------|
| Whole sample (n = 144)                               | 4.9                      | 0.1 | <.001 | 833.7 | 89.8 | Ref. | 92.0 | 8.7 | <.001 | 3597.9 | 339.5 | <.001 |
| Sex                                                  |                          |    |   |   |                          |   |   |   |                          |   |   |   |                          |
| Women (n = 104)                                       | 5.0                      | 0.1 | <.001 | 812.0 | 103.3 | Ref. | 98.3 | 11.9 | <.001 | 3690.6 | 663.9 | <.001 |
| Men (n = 40)                                          | 4.8                      | 0.1 | <.001 | 892.7 | 183.0 | Ref. | 95.3 | 18.5 | <.001 | 3562.9 | 397.5 | <.001 |
| Age group                                            |                          |    |   |   |                          |   |   |   |                          |   |   |   |                          |
| <80 y (n = 35)                                        | 4.8                      | 0.14 | <.001 | 1176.1 | 255.0 | Ref. | 124.8 | 23.9 | <.001 | 4832.0 | 919.1 | <.001 |
| ≥80 y (n = 109)                                       | 5.0                      | 0.08 | <.001 | 746.4 | 91.7 | Ref. | 83.4 | 9.0 | <.001 | 3272.8 | 352.7 | <.001 |

Ref., reference.
All participants received 2 doses of BNT162b2 vaccine 3 weeks apart and a third dose of an mRNA vaccine (mRNA-1273 or BNT162b2) between 6 and 9 months from the first vaccine dose. GMs were compared across the 4 time points (T1 is the reference).

4. Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021;10:100208.
5. Blain H, Tuaillon E, Gamon L, et al. Strong decay of SARS-CoV-2 spike antibodies after 2 BNT162b2 vaccine doses and high antibody response to a third dose in nursing home residents. J Am Med Dir Assoc. 2022;23:750–753.
6. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398:2093–2100.
7. Abbatecola AM, Incalzi RA, Malara A, et al. Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study. J Am Med Dir Assoc. 2022;23:750–753.

Giorgio Fedele, PhD
Department of Infectious Disease, Istituto Superiore di Sanità, Rome, Italy
Annapina Palmieri, MSc
Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità, Rome, Italy
Alba Malara, MD
ANASTE Humanitas Foundation, Rome, Italy
Cecilia Damiano, MSc, Anna Di Lonardo, MSc
Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità, Rome, Italy
Ilaria Schiavoni, BSc, Pasqualina Leone, ASc
Department of Infectious Disease, Istituto Superiore di Sanità, Rome, Italy
Giuseppina Panduri, ASc, Pasquale Minchella, MD
Department of Microbiology and Virology, Pugliese Ciaccio Hospital, Catanzaro, Italy
Francesco Talarico, MD
Medical Direction, De Lellis Hospital, Catanzaro, Italy
Anna Teresa Palamara, MD, Paola Stefanelli, PhD
Department of Infectious Disease, Istituto Superiore di Sanità, Rome, Italy
Raffaele Antonelli Incalzi, MD, PhD
Geriatrics Unit, Department of Medicine, Campus Bio-Medico University and Teaching Hospital, Rome, Italy
Graziano Onder, MD, PhD
Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità, Rome, Italy

http://dx.doi.org/10.1016/j.jamda.2022.05.006

Administrator Turnover in Oregon Assisted Living and Residential Care Communities, March 2020–February 2021

The impact of the COVID-19 pandemic on residents and staff of assisted living and residential care (AL/RC) facilities has been sizable, yet little is known about how the pandemic affected their administrators and their job stability. Considering the crucial role that administrators play in the delivery of high-quality care and staffing in residential long-term settings, this research letter describes the turnover experience among Oregon AL/RC administrators and its organizational and structural correlates during the first year of the COVID-19 pandemic (March 2020–February 2021).

Administrative records were retrieved from Oregon Department of Human Services (the licensing agency) for 549 AL/RC facilities licensed and operated during the study period (see Supplemental Material for details about AL/RC licensing in Oregon). The dependent variable was a community-level binary indicator that measured whether the administrator as of March 1, 2020, had left their position by February 28, 2021 (stayers = 0, leavers = 1). Organizational characteristics included in the analysis were the number of licensed beds, whether the AL/RC facility was endorsed for memory care (MC) (0 = non-MC, 1 = MC), whether the AL/RC facility had a contract to serve Medicaid residents (0 = non-Medicaid, 1 = Medicaid), nonprofit status (0 = for-profit, 1 = nonprofit), and the tenure of...

The author declares no conflicts of interest.